Question

In the Calvin cycle more atp than nadph is used how is this difference made up

Answer 1

Answer:

Explanation:

The detailed description of photosynthesis is that chlorophyll a becomes oxidized chlorophyll a after being irradiated, and the water in the thylakoid is oxidized by oxidized chlorophyll a to form oxygen and hydrogen ions, and hydrogen ions pass through the class. The ATP synthase on the capsule membrane passes through the membrane into the chloroplast matrix, where it provides a certain chemical potential (ie, an energy produced from a high concentration to a low concentration), and then ADP and Pi on the membrane. Will get energy to form ATP; and NADPH+ is the front chlorophyll a is oxidized by light to release high-energy electrons e, e will be transferred to NADP+ (oxidized coenzyme II), the photolysis of the front water does not produce hydrogen ions? This led to the combination of NADP and H+, which became NADPH.

Next, their use, in front of the photoreaction, in the dark reaction, CO2 will react with the five-carbon compound in the chloroplast matrix, fixed to the formation of a three-carbon compound (one C in CO2, five C in five-carbon compound, Two three-carbon compounds are formed, and then ATP and NADPH supply hydrogen, respectively, and then return to ADP+Pi and NADP+, and the reduced three-carbon compound becomes organic (mostly sugar) and becomes The five-carbon compound will react with CO2 again, which is the Calvin cycle.

Genetic mutation is an important factor that contributes to the pathogenesis and development of Alzheimer’s disease (AD). The genetic factors studied include the dominant mutations of genes encoding amyloid-β precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2). Additionally, more and more genes have been found to be potentially associated with AD, such as apolipoprotein E (APOE), glycogen synthase kinase 3 beta (GSK3B), dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A), and Tau. Although many studies on the treatment of AD have not been successful, gene therapy is still considered as a potential way against AD, and some gene-therapy-based therapeutics have entered the clinical trial stage. Existing strategies for gene therapy against AD include gene inactivation, genetic modification, and immunoregulation, etc.

https://www.creativebiomart.net/alzheimacy/therapeutics/gene-therapy/